Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is AMGN's Cash And Short-Term Investments?

  Amgen Inc ( AMGN ) |
1986 - 2021 (36 years)

Cash And Short-Term Investments is 
$44.2B (1Y -23.5% )

AMGN Stock Price & Cash And Short-Term Investments

Cash And Short-Term Investments for AMGN competitors.
ALXN CELG GILD BIIB GSK BMY JNJ PFE ABBV
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Cash And Short-Term Investments

chevron_right 2021 $10.6B +158x
( +15.1% / year avg)
chevron_left 1986 $66.6M
vertical_align_top Peak $157.1B +2725x
vertical_align_bottom Bottom $57.6M
arrow_drop_up # Up Years 28 28 of 36
years up.
arrow_drop_down # Down Years 8
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • AMGN's stock price has rallied +113,400% from $0.22 in 1986 , or +7.13x faster than it's cash and short-term investments over the same period.
  • If AMGN grows it's stock at the same rate as it's cash and short-term investments (+15.1%/year) , it's stock price will grow +408% and hit $1006.96 over the next 10 years.
  • AMGN's stock price has gone up 0 of the 28 years (0%) it's cash and short-term investments were also up.
  • AMGN Historical Cash And Short-Term Investments Table
    in $ million
    Year Cash And Short-Term Investments YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $10,647 -73.8% - -
    4/1/2020 $40,704 -58.6% - -
    4/1/2019 $98,216 -26.2% - -
    4/1/2018 $133,166 -15.2% - -
    4/1/2017 $157,061 12.9% - -
    4/1/2016 $139,136 20.7% - -
    4/1/2015 $115,257 23.3% - -
    4/1/2014 $93,466 4.0% - -
    4/1/2013 $89,908 2.3% - -
    4/1/2012 $87,864 26.2% - -
    4/1/2011 $69,628 19.9% - -
    4/1/2010 $58,054 26.5% - -
    4/1/2009 $45,908 34.9% - -
    4/1/2008 $34,038 52.2% - -
    4/1/2007 $22,370 6.3% - -
    4/1/2006 $21,053 6.1% - -
    4/1/2005 $19,834 11.9% - -
    4/1/2004 $17,731 -8.7% - -
    4/1/2003 $19,431 14.7% - -
    4/1/2002 $16,936 83.7% - -
    4/1/2001 $9,219 85.6% - -
    4/1/2000 $4,967 47.3% - -
    4/1/1999 $3,371 456.6% - -
    4/1/1998 $605 -39.7% - -
    4/1/1997 $1,005 76.2% - -
    4/1/1996 $570 -24.0% - -
    4/1/1995 $750 7.0% - -
    4/1/1994 $700 55.8% - -
    4/1/1993 $449 21.9% - -
    4/1/1992 $368 0.5% - -
    4/1/1991 $367 68.0% - -
    4/1/1990 $218 63.1% - -
    4/1/1989 $133 26.8% - -
    4/1/1988 $105 83.3% - -
    4/1/1987 $57 -13.5% - -
    4/1/1986 $66 - - -

  • About
    Industry: Drug Manufacturers General
    Sector: Healthcare
    Country: US
    IPO Date: 5/1/1987
    Stonk Exchange: NASDAQ
    • Amgen, Inc
    • is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics.
    • The company is headquartered in Thousand Oaks, California and currently employs 21,500 full-time employees.
    • The firm discovers, develops, manufactures and delivers various human therapeutics.
    • The company operates in human therapeutics segment.
    • Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
    • The company focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience.
    • Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

  • The sum of cash, cash equivalents, and short-term equivalents.

    Cash is self-explanatory.

    Cash equivalents are investments securities that are meant for short-term investing; they have high credit quality and are highly liquid.

    Cash equivalents, also known as "cash and equivalents," are one of the three main asset classes in financial investing, along with stocks and bonds. These securities have a low-risk, low-return profile and include U.S. government Treasury bills, bank certificates of deposit, bankers' acceptances, corporate commercial paper, and other money market instruments.

    Short-term investments, also known as marketable securities or temporary investments, are those which can easily be converted to cash, typically within 5 years.

    Many short-term investments are sold or converted to cash after a period of only 3-12 months. Some common examples of short term investments include CDs, money market accounts, high-yield savings accounts, government bonds and Treasury bills. Usually, these investments are high-quality and highly liquid assets or investment vehicles.

    For more detailed definitions, please see Investopedia.